Register Free
Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Trial Radar • ClinicalTrials.gov • Registry-linked

Trial Radar

1963 clinical trials with phase, status, specialty and registry links, summarised for rapid clinical review.

1963 recruiting AI clinical summaries
Explore Trial Collections Follow research updates
All Phases Phase I Phase II Phase III Phase IV
Therapeutic Area: All Cardiology / Cardiovascular Dermatology Diabetes / Metabolic Gastroenterology Haematology Infectious Disease Men's Health Mental Health / Psychiatry Nephrology Neurology Oncology Rare Diseases
🔬
Trial Radar

Clinical Trial Intelligence

● Recruiting Phase III Oncology
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
What is being tested: Saruparib (a PARP inhibitor) combined with camizestrant (an estrogen receptor degrader) versus standard CDK4/6 inhibitor plus endocrine therapy in patients…
14 Apr 2026 NCT06380751
● Recruiting Phase II Oncology
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Drug being tested: INCB123667, a novel therapeutic agent being evaluated for safety and efficacy in patients with platinum-resistant ovarian cancer (PROC) who have Cyclin…
14 Apr 2026 NCT07023627
● Recruiting Phase II Oncology
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Two drug combinations tested for advanced lung cancer with EGFR mutations: amivantamab plus lazertinib versus amivantamab plus chemotherapy.
13 Apr 2026 NCT06667076
● Recruiting
A Study on Hemolytic Disease of the Fetus and Newborn (HDFN) Through Global Registry
Global registry tracking anemia risk in babies of mothers at risk for blood incompatibility disease receiving standard care.
13 Apr 2026 NCT07194070
active not recruiting Phase III
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
CAR-T cell therapy cilta-cel compared with standard chemotherapy in patients with relapsed multiple myeloma resistant to lenalidomide.
13 Apr 2026 NCT04181827
● Recruiting Phase III
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Trial testing whether adding bleximenib to venetoclax-azacitidine improves outcomes in newly diagnosed AML with specific genetic mutations.
13 Apr 2026 NCT06852222
active not recruiting
ATTUNE® Revision- Complex Primary in Total Knee Arthroplasty Population
ATTUNE® Revision knee implants showed good five-year outcomes in complex primary knee replacement surgery using fixed or rotating tibial components.
13 Apr 2026 NCT03153449
active not recruiting Phase III Oncology
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
Adding niraparib to standard prostate cancer treatment (abiraterone and prednisone) delays cancer progression compared to standard treatment alone.
13 Apr 2026 NCT03748641
active not recruiting Phase II Cardiology / Cardiovascular
A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis
Trial testing a new drug combination for heart-involved amyloid disease, comparing immediate versus delayed treatment timing.
13 Apr 2026 NCT05250973
● Recruiting Phase II / Phase III
A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
Aficamten improves symptoms and safety in children with obstructive hypertrophic cardiomyopathy, a serious heart muscle condition.
13 Apr 2026 NCT06412666
● Recruiting
Abbott Structural Heart Device Registry
Real-world safety study tracking Abbott's heart devices after commercial release to meet regulatory requirements.
13 Apr 2026 NCT06590467
● Recruiting Phase III Oncology
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
Trial testing new drug epcoritamab combined with existing treatments for untreated follicular lymphoma, measuring safety and effectiveness in 1095 patients.
13 Apr 2026 NCT06191744
● Recruiting Phase II Oncology
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Amivantamab injection tested for safety and effectiveness in advanced cancers, particularly lung cancer with specific genetic mutations.
13 Apr 2026 NCT05498428
● Recruiting Phase III Infectious Disease
BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies
Trial testing a group B streptococcus vaccine in pregnant women and babies to assess safety and immune response.
13 Apr 2026 NCT07160244
● Recruiting Phase III Oncology
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
New hormone therapy drug tested against standard treatment in early breast cancer patients who've completed two years of initial hormone therapy.
13 Apr 2026 NCT05774951
active not recruiting Phase II Cardiology / Cardiovascular
A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension
Study testing whether adult-based selexipag doses produce similar blood levels in children aged 2-18 with pulmonary arterial hypertension.
13 Apr 2026 NCT03492177
active not recruiting Phase III Oncology
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
TAR-200 compared to standard chemotherapy for bladder cancer recurrence after BCG in patients refusing surgery.
13 Apr 2026 NCT06211764
active not recruiting Phase I Oncology
A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer
This trial compares different formulations of niraparib and abiraterone acetate to ensure they work similarly in men with advanced prostate cancer.
13 Apr 2026 NCT04577833
● Recruiting Oncology
Clinical Investigation Evaluating the Performance, Safety and Clinical Benefit of the Endowave FlexAblate™ Microwave Ablation System in Patients Undergoing Lung Ablation Procedures.
What is being tested: The Endowave FlexAblate™ Microwave Ablation System's effectiveness and safety profile for treating lung cancer nodules using microwave ablation technology as…
10 Apr 2026 NCT07291973
● Recruiting Phase II
BAY3401016; Biomarker Study Alport
What is being tested: BAY3401016 is being investigated as a potential therapeutic intervention in Alport syndrome, a rare genetic disorder caused by mutations in…
10 Apr 2026 NCT07211685
● Recruiting Phase II
A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
What is being tested: MZE829, an investigational therapeutic agent, is being evaluated for its safety, tolerability, and ability to reduce albuminuria (protein in urine)…
10 Apr 2026 NCT06830629
● Recruiting Phase I Respiratory / COPD / Asthma
NAL ER IPF Respiratory Function and Safety Study
What is being tested: Escalating doses of NAL ER (N-acetylcysteine extended-release) to evaluate its safety, tolerability, and effects on respiratory function in idiopathic pulmonary…
10 Apr 2026 NCT07036029
● Recruiting Phase II Respiratory / COPD / Asthma
Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma.
Treatment being tested: Lunsekimig (SAR443765), a novel therapeutic agent, is being evaluated for long-term safety and efficacy in adults with asthma through an open-label…
10 Apr 2026 NCT06609239
● Recruiting Phase II Respiratory / COPD / Asthma
A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)
What is being tested: Axatilimab (a CSF1R inhibitor) is being evaluated against best available therapy in paediatric patients with chronic graft-versus-host disease (cGVHD) who…
10 Apr 2026 NCT07124078
● Recruiting Phase III Respiratory / COPD / Asthma
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
What is being tested: Depemokimab, a biologic therapy administered as an add-on treatment, is being evaluated for efficacy and safety in patients with uncontrolled…
10 Apr 2026 NCT06961214
● Recruiting Phase II Cardiology / Cardiovascular
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
What is being tested: DM199 (rinvecalinase alfa), a novel therapeutic agent designed to improve outcomes in acute ischemic stroke caused by small and medium…
10 Apr 2026 NCT05065216
● Recruiting Cardiology / Cardiovascular
Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension
What is being tested: The Symplicity Spyral catheter system for renal denervation targeting the main and first-order branch renal arteries to achieve shorter procedure…
10 Apr 2026 NCT07115953
● Recruiting Cardiology / Cardiovascular
iCorMicA – Stratified Medicine in Angina
What is being tested: Stratified medical therapy guided by an adjunctive interventional diagnostic procedure (IDP) during invasive management of angina patients with known coronary…
10 Apr 2026 NCT04674449
● Recruiting Cardiology / Cardiovascular
Inari VISION Registry
What is being tested: The Inari VISION Registry collects real-world performance data on Inari Medical devices and products through prospective, multicenter observation without randomization,…
10 Apr 2026 NCT06600542
● Recruiting Phase II Cardiology / Cardiovascular
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
What is being tested: CSL300 (clazakizumab), an IL-6 pathway inhibitor, is being evaluated in a two-part trial to identify optimal dosing (phase 2b) and…
10 Apr 2026 NCT05485961
● Recruiting Phase III Cardiology / Cardiovascular
A Study of Navenibart in Participants With Hereditary Angioedema
What is being tested: Navenibart, a subcutaneous treatment for hereditary angioedema (HAE types 1 and 2), is being evaluated in a Phase 3 randomised…
10 Apr 2026 NCT06842823
● Recruiting Cardiology / Cardiovascular
Smartphone Twelve-Lead ECG Utility In ST-Elevation Myocardial Infarction II
What is being tested: The clinical utility and diagnostic accuracy of smartphone-based ECG devices (AliveCor Kardia) for detecting and managing ST-elevation myocardial infarction (STEMI),…
10 Apr 2026 NCT06271577
● Recruiting Phase III Oncology
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
What is being tested: Safety and risk of tumor lysis syndrome (TLS) in treatment-naïve adults with CLL receiving venetoclax combined with either intravenous obinutuzumab…
10 Apr 2026 NCT06428019
● Recruiting Phase III Oncology
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
What is being tested: Rilvegostomig (a novel VEGF inhibitor) combined with fluoropyrimidine chemotherapy and trastuzumab deruxtecan (T-DXd) versus standard trastuzumab plus chemotherapy with pembrolizumab…
10 Apr 2026 NCT06764875
● Recruiting Phase I Oncology
A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment.
What is being tested: Neoadjuvant ipilimumab (an immune checkpoint inhibitor) administered before standard surgical treatment in newly diagnosed glioblastoma patients, evaluating both safety and…
10 Apr 2026 NCT07134842
● Recruiting Phase I Oncology
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
What is being tested: YL201 (an investigational cancer therapy) combined with atezolizumab (an immune checkpoint inhibitor) in a phase Ib/II dose escalation and expansion…
10 Apr 2026 NCT07407933
● Recruiting Oncology
Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma
What is being tested: Zn-DDC (Imuthiol), an intravenous agent designed to target cancer stem cells in multiple myeloma by disrupting the hypoxia-NFkappaB-CSC pathway, which…
10 Apr 2026 NCT04234022
● Recruiting Phase III Oncology
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
What is being tested: Ficlatuzumab (a hepatocyte growth factor inhibitor) combined with cetuximab versus placebo plus cetuximab in patients with recurrent or metastatic HPV-negative…
10 Apr 2026 NCT06064877
active not recruiting Phase III
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
Trial testing selinexor combined with ruxolitinib versus ruxolitinib alone for untreated myelofibrosis patients.
09 Apr 2026 NCT04562389
● Recruiting Phase II
BAY3401016; Biomarker Study Alport
BAY3401016 is a new drug that blocks a protein to slow kidney damage progression in adults with rapidly worsening Alport syndrome.
09 Apr 2026 NCT07211685
active not recruiting Phase II Cardiology / Cardiovascular
Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
Long-term safety and effectiveness study of seralutinib, a new drug treatment, in adults with pulmonary arterial hypertension.
09 Apr 2026 NCT04816604
● Recruiting Phase I
Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]GRT6019
This study tracks how the body absorbs, breaks down and eliminates a single dose of an experimental drug called GRT6019.
09 Apr 2026 NCT07479745
active not recruiting Phase III Oncology
Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma
Nivolumab immunotherapy reduced melanoma recurrence risk compared to placebo in high-risk patients after surgery.
09 Apr 2026 NCT04099251
active not recruiting Phase III Oncology
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
TAILORx showed hormone therapy alone is sufficient for most women with early-stage hormone-responsive breast cancer, avoiding unnecessary chemotherapy.
09 Apr 2026 NCT00310180
● Recruiting Phase III
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Trial testing two new drugs (pozelimab and cemdisiran) to slow vision loss in advanced age-related macular degeneration.
09 Apr 2026 NCT06541704
● Recruiting Phase I
Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN2230 in Healthy Participants
ALXN2230 single injection tested for safety and tolerability in healthy volunteers.
09 Apr 2026 NCT07352423
● Recruiting Phase II / Phase III Neurology
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
BHV-7000 is being tested to see if it works safely in adults with focal epilepsy that doesn't respond to current drugs.
09 Apr 2026 NCT06309966
● Recruiting Phase III Oncology
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
New drug rilvegostomig combined with chemotherapy and trastuzumab deruxtecan tested against standard immunotherapy treatment for advanced HER2-positive stomach cancer.
09 Apr 2026 NCT06764875
● Recruiting Phase III Oncology
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
Trial testing whether adding ficlatuzumab to cetuximab improves survival in advanced HPV-negative head and neck cancer.
09 Apr 2026 NCT06064877
● Recruiting Oncology
Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma
One-sentence summary: Researchers are testing whether Imuthiol, a cheap drug toxic to cancer stem cells, could be effective alone or combined with existing myeloma…
09 Apr 2026 NCT04234022